Rationale and Design of the Advor (Acetazolamide in Decompensated Heart Failure with Volume Overload) Trial
Wilfried Müllens(Ziekenhuis Oost-Limburg), Matthias Dupont(Inserm), Frank Ruschitzka(Kantonsspital St. Gallen), Gerasimos Filippatos(National and Kapodistrian University of Athens), Pieter Martens(Ziekenhuis Oost-Limburg), Petra Nijst(Inserm), Pierre Troisfontaines(Inserm), Katrien Tartaglia(Inserm), Frederik H. Verbrugge(Vrije Universiteit Brussel), Kevin Damman(University Medical Center Groningen), Evi Theunissen(Ziekenhuis Oost-Limburg), Johan Lassus(University of Helsinki), Alexandre Mebazaa(Marqueurs cardiovasculaires en situation de stress), Liesbeth Bruckers(Inserm), Walter Droogné(Inserm)
Cited by 97
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
|European Heart Journal|2011|3.5k
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008
|European Journal of Heart Failure|2008|3.5k